Business
Exicure, Inc. Reports Second Quarter 2021 Financial Results and Corporate Progress
Entered Exclusive Collaboration with Ipsen Targeting Two Rare Neurodegenerative Disorders Presented Progress in Three Promising Neuroscience Programs
About this update from Exicure, Inc.
[{"type":"text","content":"\nEntered Exclusive Collaboration with Ipsen Targeting Two Rare Neurodegenerative Disorders\n\nPresented Progress in Three Promising Neuroscience Programs including Friedreich’s Ataxia, Neuropathic Pain and Batten Disease at R&D Day\n\nAnnounced Interim Results for Phase 1b/2 trial of Cavrotolimod (AST-008) and advancement of enrollment in MCC cohort\n\n CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nExicure, Inc.® (NASDAQ:XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported financial results for the quarter ended June 30, 2021 and provided an update on corporate progress.\n\n“We continue to drive towards a number of key value inflection points across our platforms and programs,” commented Dr. David Giljohann, Exicure’s Chief Executive Officer. “Notably, we believe our momentum in neurology is particularly strong on the heels of our recently announced collaboration with Ipsen for Huntington’s disease and Angelman syndrome. Our team has also made impressive progress in our preclinical neurology pipeline, with a planned IND filing in Friedreich’s ataxia and work in pain and Batten disease using our SNA technology.”\n\nPipeline Highlights & Updates\n\nNeurology\n\nIpsen Collaboration\n\n\nOn August 2, 2021, IPSEN BIOPHARM LIMITED (Ipsen) and Exicure announced an exclusive collaboration agreement to research, develop, and commercialize novel SNAs™ as potential investigational treatments for Huntington’s disease (HD) and Angelman syndrome (AS). Under the terms of the collaboration:\n\n\nIpsen obtains two exclusive options to SNAs™ currently under discovery evaluation for HD and AS;\n\n\nExicure will be responsible for discovery and certain preclinical development activities. In the event Ipsen exercises an option with respect to the two collaboration programs, Ipsen will be responsible for further development and worldwide commercialization for the corresponding licensed product;\n\n\nExicure received a $20 million upfront payment and is eligible to receive up to $1 billion in option exercise fees and milestone payments should Ipsen opt into both programs, as well as tiered royalties.\n\n\n\n\nXCUR-FXN – Friedreich’s Ataxia\n\n\nThe Company hosted a virtual R&D Day on July 15, 2021 to present new and previously unreleased preclinical data and discuss progre...